# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K241176   
B Applicant Axis-Shield Diagnostics Ltd   
C Proprietary and Established Names Alere NT-proBNP for Alinity i   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>NBC</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1117 - B-Type NatriureticPeptide Test System</td><td rowspan=1 colspan=1>CH - ClinicalChemistry</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New device   
B Measurand: NT-proBNP   
C Type of Test: Quantitative immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The Alere NT-proBNP for Alinity i assay is a chemiluminescent microparticle immunoassay (CMIA) used for the in vitro quantitative determination of N-terminal pro B-type natriuretic peptide (NT-proBNP) in human serum and plasma on the Alinity i system.

In the emergency department, measurements of NT-proBNP are used as an aid in the diagnosis of heart failure (HF) in patients with clinical suspicion of new onset or worsening HF.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

# D Special Instrument Requirements:

Alinity i system

# IV Device/System Characteristics:

# A Device Description:

The Alere NT-proBNP for Alinity i assay is an automated, two-step immunoassay for the in vitro quantitative determination of NT-proBNP in human serum and plasma (using chemiluminescent microparticle immunoassay (CMIA) technology.

# Reagents:

Microparticles: Anti-NT-proBNP (sheep, monoclonal) coated microparticles in Bis-TRIS buffer with protein (bovine) stabilizer, non-specific binding blocking agents, and surfactant. Minimum concentration: $0 . 0 5 \%$ solids. Preservative: sodium azide.

Conjugate: Anti-NT-proBNP (mouse, monoclonal) acridinium labeled conjugate in MES buffer with protein (bovine) stabilizer and surfactant. Minimum concentration: $0 . 1 2 \mu \mathrm { g / m L }$ . Preservatives: antimicrobial agents.

Materials required but not supplied with the reagent kit include Alere NT-proBNP for Alinity i calibrators and quality controls, Alinity pre-trigger and trigger solution, Alinity-i series concentrated wash buffer and Alinity i multi-assay manual diluent.

# B Principle of Operation:

Sample and anti-NT-proBNP coated paramagnetic microparticles are combined and incubated. The NT-proBNP present in the sample binds to the anti-NT-proBNP coated microparticles. The mixture is washed. Anti-NT-proBNP acridinium-labeled conjugate is added to create a reaction mixture and incubated. Following a wash cycle, Pre-Trigger and Trigger Solutions are added.

The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the amount of NT-proBNP in the sample and the RLU detected by the system optics.

V Substantial Equivalence Information:

A Predicate Device Name(s): Elecsys ProBNP II Stat Immunoassay B Predicate 510(k) Number(s): K092649

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">te(s)•</td><td colspan="1" rowspan="1">te(s)•</td><td></td></tr><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K241176</td><td colspan="1" rowspan="1">K092649</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Alere NT-proBNP for Alinity i</td><td colspan="1" rowspan="1">Elecsys proBNP IISTAT Immunoassay</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications For Use</td><td colspan="1" rowspan="1">Immunoassay used for the in vitroquantitative determination of N-terminal pro B-type natriureticpeptide (NT-proBNP) in humanserum and plasma.This assay is to be used as an aidin the diagnosis of individualssuspected of having congestiveheart failure (CHF).</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Human serum and plasma</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test principle</td><td colspan="1" rowspan="1">Sandwich immunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measurement type</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detection Technology</td><td colspan="1" rowspan="1">Chemiluminescence</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Principle of Operation</td><td colspan="1" rowspan="1">Chemiluminescent microparticleimmunoassay (CMIA)</td><td colspan="1" rowspan="1">Electrochemiluminescentmicroparticleimmunoassay (ECLIA)</td></tr><tr><td colspan="1" rowspan="1">Results Interpretation</td><td colspan="1" rowspan="1">Negative: HF unlikely for allpatients: &lt; 300.0 pg/mLGray Zone: Indeterminate;consider other causes of NT-</td><td colspan="1" rowspan="1">125 pg/mL for &lt; 75years450 pg/mL for ≥ 75years</td></tr><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K241176</td><td colspan="1" rowspan="1">K092649</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">proBNP elevation:Age (Years) NT-proBNP (pg/mL)18 to &lt; 50  ≥ 300.0 to &lt; 450.050 to 75     ≥ 300.0 to &lt; 900.0&gt;75          ≥ 300.0 to &lt; 1800.0Positive: HF likely:Age (Years) NT-proBNP (pg/mL)18 to &lt; 50   ≥ 450.050 to 75     ≥ 900.0&gt;75          ≥ 1800.0</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Measuring Interval</td><td colspan="1" rowspan="1">15.8 to 35,000.0 pg/mL</td><td colspan="1" rowspan="1">5 to 35,000 pg/mL</td></tr><tr><td colspan="1" rowspan="1">Hook Effect</td><td colspan="1" rowspan="1">No hook effect up to 372,620pg/mL</td><td colspan="1" rowspan="1">No hook effect up to300,000 pg/mL</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline – Third Edition

CLSI EP06: Evaluation of the Linearity of Quantitative Measurement Procedures, $2 ^ { \mathrm { n d } }$ Edition

CLSI EP07: Interference Testing in Clinical Chemistry, $3 ^ { \mathrm { r d } }$ Edition

CLSI EP12: Evaluation of Qualitative, Binary Output Examination Performance, $3 ^ { \mathrm { r d } }$ Edition

CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedure; Approved Guideline – Second Edition

CLSI EP25: Evaluation of Stability of In Vitro Medical Laboratory Test Reagents, $2 ^ { \mathrm { n d } }$ Edition

CLSI EP28-A3c: Defining Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline - Third Edition

CLSI EP34: Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking, $1 ^ { \mathrm { s t } }$ Edition

CLSI EP35: Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures. $1 ^ { \mathrm { s t } }$ Edition

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

Within-Laboratory Precision (20-Day)

A study was performed based on guidance from CLSI EP05-A3.

Three controls and 8 human plasma panels (7 native panels and 1 panel supplemented with NT-proBNP analyte) were tested in 2 replicates at 2 separate times per day over 20 days (for a total of 80 measurements per sample). Testing was conducted using 3 lots of the candidate device, 1 lot of the Alere NT-proBNP for Alinity i Calibrators, 1 lot of the Alere NT-proBNP for Alinity i Controls, and 1 Alinity i instrument.

Panels (Panel A to Panel G) were prepared by pooling NT-proBNP $\mathrm { K } _ { 2 }$ EDTA plasma specimens and diluting with human K2EDTA plasma as necessary to achieve the target concentrations. Panel H was prepared by spiking $\mathrm { K } _ { 2 }$ EDTA plasma with a synthetic NT‑proBNP peptide. The sponsor provided evidence to show that the contrived samples mimic patient samples.

Results are summarized in the table below:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=2>Repeatability(Within-Run)</td><td rowspan=1 colspan=2>Within-Laboratorya</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>OverallWithin-Laboratoryb</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>LowControl</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>143.0</td><td rowspan=1 colspan=1>6.40</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>7.63</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>8.82</td><td rowspan=1 colspan=1>6.2</td></tr><tr><td rowspan=1 colspan=1>MediumControl</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>503.4</td><td rowspan=1 colspan=1>16.26</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>18.21</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>9.29</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>20.44</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>HighControl</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>5144.2</td><td rowspan=1 colspan=1>177.02</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>202.18</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>21.47</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>203.32</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Panel A</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>18.8</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>1.72</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>10.0</td></tr><tr><td rowspan=1 colspan=1>Panel B</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>55.6</td><td rowspan=1 colspan=1>2.64</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>3.02</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>3.41</td><td rowspan=1 colspan=1>6.1</td></tr><tr><td rowspan=1 colspan=1>Panel C</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>130.4</td><td rowspan=1 colspan=1>4.28</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>5.44</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>4.87</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>7.30</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>Panel D</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>449.1</td><td rowspan=1 colspan=1>13.10</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>18.68</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>14.02</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>23.36</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>Panel E</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>1011.4</td><td rowspan=1 colspan=1>28.31</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>34.49</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>21.92</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>40.87</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Panel F</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>1938.0</td><td rowspan=1 colspan=1>54.02</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>65.28</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>22.56</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>69.07</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>Panel G</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>14939.8</td><td rowspan=1 colspan=1>417.56</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>518.88</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>296.61</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>597.67</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Panel H</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>31711.0</td><td rowspan=1 colspan=1>989.02</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1185.11</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>2118.19</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>2427.19</td><td rowspan=1 colspan=1>7.7</td></tr></table>

a Includes repeatability (within-run), between-run, and between-day variability b Includes repeatability (within-run), between-run, between-day, and between-lot variability

# Reproducibility

A study was performed based on guidance from CLSI EP05-A3.

Testing was conducted at 3 sites, using 3 lots of the candidate device, 2 lots of the Alere NTproBNP for Alinity i Calibrators, 2 lots of the Alere NT-proBNP for Alinity i Controls, and 1 Alinity i instrument.

Three controls and 8 reproducibility panel plasma members were tested in 4 replicates at 2 separate times per day on 5 different days.

The native panel members 1 to 6 were prepared by pooling NT-proBNP K2EDTA plasma specimens and diluting with human ${ \mathrm { K } } _ { 2 }$ EDTA plasma as necessary to achieve the target concentration. Panel 7 and Panel 8 were prepared by spiking K2EDTA plasma with a synthetic NT‑proBNP peptide. Results are summarized in the table below:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-Laboratorya</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>OverallReproducibilityb</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>LowControl</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>136.6</td><td rowspan=1 colspan=1>4.75</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>5.75</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>2.63</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.45</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>6.49</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>MediumControl</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>477.1</td><td rowspan=1 colspan=1>12.24</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>15.35</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>14.20</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>8.88</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>22.72</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>HighControl</td><td rowspan=1 colspan=1>359</td><td rowspan=1 colspan=1>4932.2</td><td rowspan=1 colspan=1>201.01</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>311.08</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>105.17</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>328.38</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>359</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>2.10c</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>2.74c</td><td rowspan=1 colspan=1>18.9</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.74c</td><td rowspan=1 colspan=1>18.9</td></tr><tr><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>51.9</td><td rowspan=1 colspan=1>2.14</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>3.07</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.11</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>127.1</td><td rowspan=1 colspan=1>4.67</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>5.95</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>6.15</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>436.9</td><td rowspan=1 colspan=1>10.46</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>18.67</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>3.18</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>18.94</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>Panel 5</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>996.5</td><td rowspan=1 colspan=1>21.86</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>43.45</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>17.12</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>46.70</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>Panel 6</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>1891.1</td><td rowspan=1 colspan=1>33.18</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>79.86</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>35.96</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>87.58</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>Panel 7</td><td rowspan=1 colspan=1>359</td><td rowspan=1 colspan=1>15664.6</td><td rowspan=1 colspan=1>319.91</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>974.61</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>281.81</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>217.28</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1037.54</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>Panel 8</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>25630.5</td><td rowspan=1 colspan=1>601.42</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1654.86</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>220.39</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>807.19</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1854.37</td><td rowspan=1 colspan=1>7.2</td></tr></table>

a Includes repeatability, between-run, and between-day variance components b Includes repeatability, between-run, between-day, between-site, and between-lot variance components c An outlying run was observed. Based on guidance from CLSI EP05-A3, a replacement run was performed. Without the replacement run, the repeatability SD was $9 . 5 3 ~ \mathrm { p g / m L }$ $( 1 . 1 2 \mathrm { p m o l } / \mathrm { L } )$ , within-laboratory SD was $9 . 6 4 ~ \mathrm { p g / m L }$ (1.14 pmol/L), and the overall reproducibility SD was $9 . 6 4 ~ \mathrm { p g / m L }$ $\mathrm { ( 1 . 1 4 p m o l / L ) }$ ).

2. Linearity:

A linearity study was performed based on guidance from CLSI EP06, 2nd ed.

Two linearity $\mathrm { K } _ { 2 } \mathrm { E D T A }$ plasma sample sets were prepared, each containing 8-9 concentration levels. Each linearity panel was a dilution series prepared by intermixing known volumes of high native sample with analyte-free plasma. The samples were tested in replicates of 10 using 3 reagent lots, 1 calibrator lot, 1 control lot, and 1 Alinity i instrument. All samples within the sample set were tested within a single run.

The linearity was analyzed separately for each reagent lot per sample type. Using a weighted linear regression analysis, the difference and percent difference between the mean observed concentration and the expected concentration of each sample were calculated. At each concentration, the deviation from linearity was less than $1 1 . 3 \%$ .

The results of the linearity study support the claimed measuring range of 15.8 to 35,000.0 $\boldsymbol { \mathrm { p g / m L } }$ .

# Sample Dilution

Plasma samples with NT-proBNP concentrations up to $7 0 { , } 0 0 0 \ \mathrm { p g / m L }$ can be measured after a 1:2 auto dilution, and samples with NT-proBNP concentrations up to $3 5 0 , 0 0 0 \mathrm { p g / m L }$ can be measured using a 1:10 manual dilution. The percent recovery of diluted samples ranged from $9 2 . 1 \%$ to $1 0 3 . 4 \%$ .

# 3. Analytical Specificity/Interference:

Interference studies were performed based on guidance from CLSI EP07, 3rd ed.

# Endogenous Substances

Interference from endogenous substances was assessed using $\mathrm { K } _ { 2 } \mathrm { E D T A }$ plasma samples at two levels of NT-proBNP analyte (approximately $1 2 5 \mathrm { p g / m L }$ and $2 0 0 0 \mathrm { p g / m L }$ ). Each sample was divided into 2 aliquots: one aliquot for the test sample (with added interferent) and one aliquot for the control sample (without added interferent). Each sample was tested in replicates of 30 using one Alinity i Analyzer, three reagent lots, and one calibrator lot.

No significant interference (defined by the sponsor as a difference within $\pm 1 0 \%$ between the mean for the test sample versus the mean of the reference samples) was observed at the following concentrations:

<table><tr><td rowspan=1 colspan=1>Potentially Interfering Substance</td><td rowspan=1 colspan=1>Highest concentration tested at which nosignificant interference is observed</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (unconjugated)</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>4250 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>700 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Human Anti-Mouse Antibodies (HAMA)</td><td rowspan=1 colspan=1>1500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>1 g/dL</td></tr><tr><td rowspan=1 colspan=1>IgG</td><td rowspan=1 colspan=1>6 g/dL</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>3000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (RF)</td><td rowspan=1 colspan=1>600 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Total Protein</td><td rowspan=1 colspan=1>12.6 g/dL</td></tr></table>

Interference beyond $\pm 1 0 . 0 \%$ (based on $9 5 \%$ Confidence Interval [CI]) was observed at the concentrations shown below for the following substances.

<table><tr><td colspan="1" rowspan="1">Potentially InterferingSubstance</td><td colspan="1" rowspan="1">Interferent Level</td><td colspan="1" rowspan="1">Analyte Level</td><td colspan="1" rowspan="1">% Interference(95% CI)</td></tr><tr><td colspan="1" rowspan="1">RF</td><td colspan="1" rowspan="1">1520 IU/mL</td><td colspan="1" rowspan="1">125 pg/mL</td><td colspan="1" rowspan="1">-8.9%(-10.4%, -7.5%)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1520 IU/mL</td><td colspan="1" rowspan="1">2000 pg/mL</td><td colspan="1" rowspan="1">-11.4%(-12.4%, -10.4%)</td></tr><tr><td colspan="1" rowspan="2">Total Protein</td><td colspan="1" rowspan="1">15.2 g/dL</td><td colspan="1" rowspan="1">125 pg/mL</td><td colspan="1" rowspan="1">-12.7%(-14.7%, -10.7%)</td></tr><tr><td colspan="1" rowspan="1">15.5 g/dL</td><td colspan="1" rowspan="1">2000 pg/mL</td><td colspan="1" rowspan="1">-9.9%(-11.4%, -8.5%)</td></tr></table>

# Potentially Interfering Drugs

Interference from exogenous substances was assessed using $\mathrm { K } _ { 2 } \mathrm { E D T A }$ plasma samples at two levels of the NT-proBNP analyte (approximately $1 2 5 \mathrm { p g / m L }$ and $2 0 0 0 \mathrm { p g / m L }$ ), following the same procedure as for endogenous substances.

No significant interference (defined by the sponsor as a difference within $\pm 1 0 \%$ between the mean for the test sample versus the mean of the reference samples) was observed at the following concentrations:

<table><tr><td colspan="1" rowspan="1">Potentially Interfering Drug</td><td colspan="1" rowspan="1">Highest concentration tested at which nosignificant interference is observed</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">15.6 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">60 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Allopurinol</td><td colspan="1" rowspan="1">6.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Amikacin</td><td colspan="1" rowspan="1">15 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Amiodarone</td><td colspan="1" rowspan="1">4.2 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Amlodipine Besylate</td><td colspan="1" rowspan="1">0.4 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">7.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ascorbic acid</td><td colspan="1" rowspan="1">5.25 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Atenolol</td><td colspan="1" rowspan="1">1.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Atorvastatin</td><td colspan="1" rowspan="1">32 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">10.8 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Captopril</td><td colspan="1" rowspan="1">5.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">4.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Carvedilol</td><td colspan="1" rowspan="1">3.75 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Chloramphenicol</td><td colspan="1" rowspan="1">7.8 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide</td><td colspan="1" rowspan="1">1.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">0.33 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Cimetidine</td><td colspan="1" rowspan="1">3.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Cinnarizine</td><td colspan="1" rowspan="1">3.1 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Clopidogrel bisulfate</td><td colspan="1" rowspan="1">7.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">30 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Cyclosporine A</td><td colspan="1" rowspan="1">0.4 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Dextran 40</td><td colspan="1" rowspan="1">6000 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">3.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Diclofenac</td><td colspan="1" rowspan="1">6.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">0.025 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Diltiazem</td><td colspan="1" rowspan="1">12 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Dipyridamole</td><td colspan="1" rowspan="1">8.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Disopyramide</td><td colspan="1" rowspan="1">4.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Dobutamine</td><td colspan="1" rowspan="1">10 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Dopamine</td><td colspan="1" rowspan="1">65 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Enalapril Maleate</td><td colspan="1" rowspan="1">1.6 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Epinephrine</td><td colspan="1" rowspan="1">0.05 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">13.8 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ethanol</td><td colspan="1" rowspan="1">600 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ethosuximide</td><td colspan="1" rowspan="1">30 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Fenofibrate</td><td colspan="1" rowspan="1">4.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">6.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">12 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Heparin</td><td colspan="1" rowspan="1">8 U/mL</td></tr><tr><td colspan="1" rowspan="1">Hydralazine</td><td colspan="1" rowspan="1">2.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Hydrochlorothiazide</td><td colspan="1" rowspan="1">2.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Insulin</td><td colspan="1" rowspan="1">0.16 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">50 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Indomethacin</td><td colspan="1" rowspan="1">3.6 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Isosorbide dinitrate</td><td colspan="1" rowspan="1">6.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Lidocaine</td><td colspan="1" rowspan="1">8.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Lisinopril</td><td colspan="1" rowspan="1">1.6 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Lithium</td><td colspan="1" rowspan="1">4.20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Losartan potassium</td><td colspan="1" rowspan="1">5.99 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Lovastatin</td><td colspan="1" rowspan="1">2.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">L-Thyroxine</td><td colspan="1" rowspan="1">0.06 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Methyldopa</td><td colspan="1" rowspan="1">2.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Methylprednisolone</td><td colspan="1" rowspan="1">0.75 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Metoprolol</td><td colspan="1" rowspan="1">1.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Milrinone</td><td colspan="1" rowspan="1">0.183 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">49.97 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">0.1 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Nicotinic acid</td><td colspan="1" rowspan="1">4.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">6.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Nitrofurantoin</td><td colspan="1" rowspan="1">4.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Nitroglycerin</td><td colspan="1" rowspan="1">0.016 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">1.2 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Oxytetracycline</td><td colspan="1" rowspan="1">10 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Penicillin G</td><td colspan="1" rowspan="1">25 U/mL</td></tr><tr><td colspan="1" rowspan="1">Pentobarbital</td><td colspan="1" rowspan="1">12.6 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Phenobarbitol</td><td colspan="1" rowspan="1">69 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Phenprocoumon (Marcumar)</td><td colspan="1" rowspan="1">1.53 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">6.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Primidone</td><td colspan="1" rowspan="1">5.7 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Probenecid</td><td colspan="1" rowspan="1">60 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Procainamide</td><td colspan="1" rowspan="1">4.8 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Propafenone</td><td colspan="1" rowspan="1">30 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Propanolol</td><td colspan="1" rowspan="1">0.2 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Propoxyphene</td><td colspan="1" rowspan="1">0.321 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Quinidine</td><td colspan="1" rowspan="1">2.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ramipril</td><td colspan="1" rowspan="1">0.6 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Retaplase</td><td colspan="1" rowspan="1">3.33 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Simvastatin</td><td colspan="1" rowspan="1">3.2 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Spironolactone</td><td colspan="1" rowspan="1">7.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Sulfamethoxazole</td><td colspan="1" rowspan="1">112 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Theophylline</td><td colspan="1" rowspan="1">6.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Tolbutamide</td><td colspan="1" rowspan="1">150 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Torasemide</td><td colspan="1" rowspan="1">1.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Trandolapril</td><td colspan="1" rowspan="1">4.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Trasylol/Aprotinin</td><td colspan="1" rowspan="1">501.8 KIE/mL</td></tr><tr><td colspan="1" rowspan="1">Trimethoprim</td><td colspan="1" rowspan="1">6.4 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">23.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Valproic Acid</td><td colspan="1" rowspan="1">50 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">24 mg/dL</td></tr><tr><td>Potentially Interfering Drug</td><td>Highest concentration tested at which no significant interference is observed</td></tr><tr><td>Warfarin</td><td>7.5 mg/dL</td></tr></table>

# Cross-Reactants

A study was conducted to evaluate the performance of the Alere NT-proBNP for Alinity i assay in the presence of potential cross-reactants.

Testing was conducted using $\mathrm { K } _ { 2 }$ EDTA samples at two levels of NT-proBNP $1 2 5 ~ \mathrm { p g / m L }$ and $2 0 0 0 ~ \mathrm { p g / m L } )$ ). Each sample was divided into 2 aliquots: one aliquot for the test sample (spiked with cross-reactant) and one aliquot for the control sample (spiked with the same diluent used for the preparation of cross-reactant in stock solutions). Each sample was tested in replicates of 30 using 1 reagent lot, 1 calibrator lot, 1 control lot, and 1 Alinity i instrument.

The $\%$ Recovery was calculated as: $\%$ Recovery $= 1 0 0 \mathrm { { x } }$ (test mean / control mean)

The observed $\%$ recovery of NT-proBNP was within $1 0 0 \% \pm 1 0 \%$ for all cross-reactants evaluated at each analyte level:

<table><tr><td rowspan=1 colspan=1>Potential Cross-Reactant</td><td rowspan=1 colspan=1>Cross-Reactant Concentration</td></tr><tr><td rowspan=1 colspan=1>Adrenomedullin</td><td rowspan=1 colspan=1>1000 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Aldosterone</td><td rowspan=1 colspan=1>600 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Angiotensin I</td><td rowspan=1 colspan=1>600 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Angiotensin II</td><td rowspan=1 colspan=1>600 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Angiotensin III</td><td rowspan=1 colspan=1>1000 pg /mL</td></tr><tr><td rowspan=1 colspan=1>ANP 28</td><td rowspan=1 colspan=1>3100 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Arg-Vasopressin</td><td rowspan=1 colspan=1>1000 pg/mL</td></tr><tr><td rowspan=1 colspan=1>BNP 32</td><td rowspan=1 colspan=1>3500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>CNP 22</td><td rowspan=1 colspan=1>2200 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Endothelin</td><td rowspan=1 colspan=1>20 pg/mL</td></tr><tr><td rowspan=1 colspan=1>NT-proANP 1-30 (preproANP26-55)</td><td rowspan=1 colspan=1>3500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>NT-proANP 31-67 (preproANP56-92)</td><td rowspan=1 colspan=1>1000 pg/mL</td></tr><tr><td rowspan=1 colspan=1>NT-proANP 79-98 (preproANP104-123)</td><td rowspan=1 colspan=1>1000 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Renin</td><td rowspan=1 colspan=1>50 000 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Urodilatin</td><td rowspan=1 colspan=1>3500 ng/mL</td></tr></table>

# High Dose Hook Effect

The Alere NT-proBNP for Alinity i assay was evaluated for high dose hook effect using K2EDTA plasma samples with 4 concentration levels of NT-proBNP. No high dose hook effect was observed on samples up to $3 7 2 { , } 6 2 0 \ \mathrm { p g / m L }$ of NT-proBNP.

# 4. Assay Reportable Range:

The analytical measuring interval (AMI) for the Alere NT-proBNP for Alinity i assay was determined to be from 15.8 to $3 5 , 0 0 0 . 0 \mathrm { p g / m L }$ .

The extended measuring interval (EMI) for the Alere NT-proBNP for Alinity i assay was determined to be from 35,000.0 to $3 5 0 , 0 0 0 . 0 \mathrm { p g / m L }$ .

The reportable interval for the Alere NT-proBNP for Alinity i assay was determined to be from 15.8 to $3 5 0 , 0 0 0 . 0 \mathrm { p g / m L }$ .

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

# Traceability

The Alere NT-proBNP for Alinity i Calibrators are traceable to internal reference standards at every concentration level that were value assigned on and made traceable to the predicate device by transference, as described by CLSI Document EP32-R.

# Specimen Stability

Specimen storage times were validated with serum separator and $\mathrm { K } _ { 2 } \mathrm { E D T A }$ plasma tube types. The sponsor has provided information to support the following claims in their labeling:

<table><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Temperature</td><td rowspan=1 colspan=1>MaximumStorage Time</td><td rowspan=1 colspan=1>Special Instructions</td></tr><tr><td rowspan=3 colspan=1>Serum/Plasma</td><td rowspan=1 colspan=1>Room temperature(20 to 25°C)</td><td rowspan=1 colspan=1>48 hours</td><td rowspan=1 colspan=1>Remove serum or plasmafrom the clot, red blood cells,or separator gel if testing willbe delayed more than 24hours.</td></tr><tr><td rowspan=1 colspan=1>2 to 8°C</td><td rowspan=1 colspan=1>3 days</td><td rowspan=1 colspan=1>Remove serum or plasmafrom the clot, red blood cells,or separator gel if testing willbe delayed more than 24hours.</td></tr><tr><td rowspan=1 colspan=1>-20°C or colder</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Remove serum or plasmafrom the clot, red blood cells,or separator gel.</td></tr></table>

Avoid more than 3 freeze/thaw cycles.

# Sample Onboard Storage

The sponsor provided data to support that samples can be stored on the Alinity i system for up to 3 hours when tested with the Alere NT-proBNP for Alinity i assay.

The LoB, LoD, and LoQ study was performed based on guidance from CLSI EP17-A2.

# Limit of Blank (LoB)

The LoB study was performed on 4 analyte-free K2EDTA plasma specimens, using 3 reagent lots, 1 calibrator lot, 1 control lot, and 2 Alinity i instruments. Testing occurred over 3 days. Samples were tested in 5 replicates on each day of testing, for a total of 60 replicates. The LoB was determined non-parametrically for each reagent lot separately and the highest value obtained from three lots was taken as the LoB value. The LoB for the Alere NT-proBNP for Alinity i assay was estimated to be $0 . 1 \ \mathrm { p g / m L }$ .

# Limit of Detection (LoD)

The LoD study was performed on 18 low-level panels (2 samples at each of 9 unique target concentration levels of approximately 3.0, 4.0, 5.0, 7.0, 9.0, 12.0, 16.0, 20.0, and 24.0 $\mathrm { p g / m L ) }$ ), using 3 reagent lots, 1 calibrator lot, 1 control lot, and 2 Alinity i instruments. Testing occurred over 3 days. The 18 low-analyte samples were tested in 10 replicates on each day of testing, for a total of 60 measurements per sample per reagent lot. The parametric approach described in CLSI EP17-A2 was followed to determine the LoD. The highest observed LoD of the three lots was the reported LoD for the assay. The LoD for the Alere NT-proBNP for Alinity i assay was estimated to be $3 . 6 \ : \mathrm { p g / m L }$ .

# Limit of Detection (LoQ)

The LoQ study was performed on 18 low-level panels (2 samples at each of 9 unique target concentration levels of approximately 3.0, 4.0, 5.0, 7.0, 9.0, 12.0, 16.0, 20.0, and 24.0 $\mathrm { p g / m L ) }$ ), using 3 reagent lots, 1 calibrator lot, 1 control lot, and 2 Alinity i instruments. Testing occurred over 3 days. The 18 low-analyte samples were tested in 10 replicates on each day of testing, for a total of 60 measurements per sample per reagent lot. The LoQ was determined as the lowest concentration of analyte at which the maximum allowable precision of $20 \%$ CV was met. The highest value obtained from three lots was the reported LoQ for the assay. The LoQ for the Alere NT-proBNP for Alinity i assay was estimated to be 15.8 $\boldsymbol { \mathrm { p g / m L } }$ .

# 7. Assay Cut-Off:

See Section VII.D for Clinical Cut-off information.

# B Comparison Studies:

1. Method Comparison with Predicate Device: Not applicable.

2. Matrix Comparison:

A study was conducted to evaluate equivalence between different blood collection tubes. The study was performed based on guidance from the CLSI document EP35 1st ed.

In the study, samples were collected from 63 subjects, representative of the intended use population. A primary tube (control condition, K2EDTA) and a minimum of 1 candidate tube (test condition) were collected from each enrolled subject. Testing of specimens collected in different tube types was initiated within 2 hours of draw. Two replicates from each specimen tube type were tested. Testing was conducted using 2 Alinity i instruments, 2 reagent lots, 3 calibrator lots, and 3 control lots.

The results were analyzed using Passing-Bablok regression analysis comparing the first replicate of the evaluation tube to the first replicate of the control tube (K2EDTA).

<table><tr><td rowspan=1 colspan=1>Tube Type</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>ConcentrationRange (pg/mL)</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>K3EDTA</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>20.2-29670.1</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>20.2-19929.3</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.993</td></tr><tr><td rowspan=1 colspan=1>SerumSeparatorTube</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>21.8-29670.1</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>LithiumHeparin</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>20.2-29670.1</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.998</td></tr><tr><td rowspan=1 colspan=1>LithiumHeparin(PlasmaSeparator)</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>20.2-29670.1</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>-1.2</td><td rowspan=1 colspan=1>1.000</td></tr></table>

The study results demonstrate equivalence between $\mathrm { K } _ { 2 }$ EDTA plasma, $\mathrm { K } _ { 3 } \mathrm { E D T A }$ plasma, lithium heparin plasma, and serum samples.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

A multi-center prospective study including 17 collection sites across the US was conducted to establish the performance characteristics of the Alere NT-proBNP for Alinity i assay. Subjects 18 years and older presenting to the emergency department (ED) with signs and symptoms consistent with a clinical suspicion of new onset or acute exacerbation of HF were included in the study. Subjects with renal insufficiency requiring dialysis or known estimated glomerular filtration rate ( $\mathrm { : G F R ) < } 1 5 \ \mathrm { m L / m i n / } 1 . 7 3 \ \mathrm { m } ^ { 2 }$ and subjects with dyspnea after chest trauma were excluded from the study. For each patient enrollment, whole blood samples

were collected in $\mathrm { K } _ { 2 } \mathrm { E D T A }$ tubes, processed to plasma, and stored frozen until testing. Data supporting the stability of the samples for the storage time and condition were provided by the sponsor.

The results were determined from 2127 ED subjects. Of the 2127 ED subjects, 1030 $( 4 8 . 4 \% )$ were female and 1097 $( 5 1 . 6 \% )$ were male, ranging in age from 19 to 97 years. Individuals in the population were White $( 5 3 . 1 \% )$ , Black or African American $( 3 9 . 4 5 \% )$ , Asian $( 1 . 7 \% )$ , American Indian or Alaska Native $( 0 . 8 \% )$ , Native Hawaiian or Other Pacific Islander $( 0 . 3 \% )$ , or represented by other races $( 0 . 9 \% )$ , with the remaining $3 . 6 \%$ of Unknown / Not Reported race. A total of 1934 $( 9 0 . 9 \% )$ ED subjects were not Hispanic or Latino, and 168 $( 7 . 9 \% )$ ED subjects were Hispanic or Latino, with the remaining 25 $( 1 . 2 \% )$ ED subjects of Unknown / Not Reported ethnicity.

The clinical study specimen testing was performed with clinical specimens that were randomly distributed across 3 clinical testing sites using 3 lots of the Alere NT-proBNP for Alinity i Reagents, 2 lots of the Alere NT-proBNP for Alinity i Calibrators, 2 lots of the Alere NT-proBNP for Alinity i Controls, and 1 Alinity i instrument at each clinical site. One replicate of each specimen was tested with the investigational device.

Adjudication was performed by a panel of 10 board-certified cardiologists. A determination of HF (acute exacerbation or new onset) or non-HF was rendered for each subject. The adjudicators were blinded to the diagnosis and HF severity of the local attending physician in the ED, and the determination of other members of the adjudication panel. For subjects determined to have HF, severity was assessed based on New York Heart Association (NYHA) classification (I, II, III, IV) and a determination of new or worsening HF.

The descriptive statistics for the Alere NT-proBNP for Alinity i test results $\mathrm { ( p g / m L ) }$ were determined within and across sex by age group and are summarized in the following table:

Alere NT-proBNP for Alinity i – All Subjects   

<table><tr><td rowspan=1 colspan=1>AdjudicatedDiagnosis</td><td rowspan=1 colspan=4>HF</td><td rowspan=1 colspan=4>Non-HF</td></tr><tr><td rowspan=1 colspan=1>Age Group(Years)</td><td rowspan=1 colspan=1>&lt;50</td><td rowspan=1 colspan=1>50 to 75</td><td rowspan=1 colspan=1>&gt;75</td><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>&lt;50</td><td rowspan=1 colspan=1>50 to 75</td><td rowspan=1 colspan=1>&gt;75</td><td rowspan=1 colspan=1>All</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>553</td><td rowspan=1 colspan=1>167</td><td rowspan=1 colspan=1>880</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>799</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>1247</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>4354.5</td><td rowspan=1 colspan=1>6092.9</td><td rowspan=1 colspan=1>6891.3</td><td rowspan=1 colspan=1>5928.3</td><td rowspan=1 colspan=1>437.9</td><td rowspan=1 colspan=1>760.4</td><td rowspan=1 colspan=1>1738.8</td><td rowspan=1 colspan=1>798.9</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>5454.61</td><td rowspan=1 colspan=1>8144.69</td><td rowspan=1 colspan=1>6860.32</td><td rowspan=1 colspan=1>7521.45</td><td rowspan=1 colspan=1>1686.57</td><td rowspan=1 colspan=1>1833.48</td><td rowspan=1 colspan=1>3494.96</td><td rowspan=1 colspan=1>2100.93</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>2664.9</td><td rowspan=1 colspan=1>3297.2</td><td rowspan=1 colspan=1>4787.6</td><td rowspan=1 colspan=1>3420.7</td><td rowspan=1 colspan=1>70.1</td><td rowspan=1 colspan=1>198.9</td><td rowspan=1 colspan=1>565.9</td><td rowspan=1 colspan=1>181.8</td></tr><tr><td rowspan=1 colspan=1>Minimum</td><td rowspan=1 colspan=1>22.8</td><td rowspan=1 colspan=1>19.8</td><td rowspan=1 colspan=1>158.9</td><td rowspan=1 colspan=1>19.8</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Maximum</td><td rowspan=1 colspan=1>38880.9</td><td rowspan=1 colspan=1>60716.9</td><td rowspan=1 colspan=1>38938.4</td><td rowspan=1 colspan=1>60716.9</td><td rowspan=1 colspan=1>24737.1</td><td rowspan=1 colspan=1>17988.9</td><td rowspan=1 colspan=1>31154.0</td><td rowspan=1 colspan=1>31154.0</td></tr></table>

Alere NT-proBNP for Alinity i – Male Subjects   

<table><tr><td rowspan=1 colspan=1>AdjudicatedDiagnosis</td><td rowspan=1 colspan=4>HF</td><td rowspan=1 colspan=4>Non-HF</td></tr><tr><td rowspan=1 colspan=1>Age Group(Years)</td><td rowspan=1 colspan=1>&lt;50</td><td rowspan=1 colspan=1>50 to 75</td><td rowspan=1 colspan=1>&gt;75</td><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>&lt;50</td><td rowspan=1 colspan=1>50 to 75</td><td rowspan=1 colspan=1>&gt;75</td><td rowspan=1 colspan=1>All</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>317</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>504</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>392</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>593</td></tr></table>

Alere NT-proBNP for Alinity i – Female Subjects   

<table><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>4522.0</td><td rowspan=1 colspan=1>6631.0</td><td rowspan=1 colspan=1>6971.2</td><td rowspan=1 colspan=1>6247.0</td><td rowspan=1 colspan=1>638.8</td><td rowspan=1 colspan=1>911.6</td><td rowspan=1 colspan=1>2258.0</td><td rowspan=1 colspan=1>999.4</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>4977.78</td><td rowspan=1 colspan=1>8410.52</td><td rowspan=1 colspan=1>6708.84</td><td rowspan=1 colspan=1>7590.10</td><td rowspan=1 colspan=1>2369.85</td><td rowspan=1 colspan=1>2084.06</td><td rowspan=1 colspan=1>4464.35</td><td rowspan=1 colspan=1>2557.26</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>2780.1</td><td rowspan=1 colspan=1>4066.5</td><td rowspan=1 colspan=1>4773.9</td><td rowspan=1 colspan=1>3904.3</td><td rowspan=1 colspan=1>64.1</td><td rowspan=1 colspan=1>221.0</td><td rowspan=1 colspan=1>701.8</td><td rowspan=1 colspan=1>203.2</td></tr><tr><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>58.3</td><td rowspan=1 colspan=1>19.8</td><td rowspan=1 colspan=1>186.9</td><td rowspan=1 colspan=1>19.8</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Max</td><td rowspan=1 colspan=1>26986.3</td><td rowspan=1 colspan=1>60716.9</td><td rowspan=1 colspan=1>32286.4</td><td rowspan=1 colspan=1>60716.9</td><td rowspan=1 colspan=1>24737.1</td><td rowspan=1 colspan=1>17988.9</td><td rowspan=1 colspan=1>31154.0</td><td rowspan=1 colspan=1>31154.0</td></tr></table>

<table><tr><td rowspan=1 colspan=1>AdjudicatedDiagnosis</td><td rowspan=1 colspan=4>HF</td><td rowspan=1 colspan=4>Non-HF</td></tr><tr><td rowspan=1 colspan=1>Age Group(Years)</td><td rowspan=1 colspan=1>&lt;50</td><td rowspan=1 colspan=1>50 to 75</td><td rowspan=1 colspan=1>&gt;75</td><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>&lt;50</td><td rowspan=1 colspan=1>50 to 75</td><td rowspan=1 colspan=1>&gt;75</td><td rowspan=1 colspan=1>All</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>376</td><td rowspan=1 colspan=1>165</td><td rowspan=1 colspan=1>407</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>654</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>4034.7</td><td rowspan=1 colspan=1>5370.1</td><td rowspan=1 colspan=1>6814.2</td><td rowspan=1 colspan=1>5501.2</td><td rowspan=1 colspan=1>273.5</td><td rowspan=1 colspan=1>614.8</td><td rowspan=1 colspan=1>1320.8</td><td rowspan=1 colspan=1>617.2</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>6302.82</td><td rowspan=1 colspan=1>7732.10</td><td rowspan=1 colspan=1>7042.32</td><td rowspan=1 colspan=1>7417.01</td><td rowspan=1 colspan=1>732.64</td><td rowspan=1 colspan=1>1543.13</td><td rowspan=1 colspan=1>2403.63</td><td rowspan=1 colspan=1>1556.92</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>1851.5</td><td rowspan=1 colspan=1>2541.7</td><td rowspan=1 colspan=1>4787.6</td><td rowspan=1 colspan=1>2786.4</td><td rowspan=1 colspan=1>73.1</td><td rowspan=1 colspan=1>174.9</td><td rowspan=1 colspan=1>499.7</td><td rowspan=1 colspan=1>161.2</td></tr><tr><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>22.8</td><td rowspan=1 colspan=1>24.9</td><td rowspan=1 colspan=1>158.9</td><td rowspan=1 colspan=1>22.8</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>25.7</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Max</td><td rowspan=1 colspan=1>38880.9</td><td rowspan=1 colspan=1>47385.1</td><td rowspan=1 colspan=1>38938.4</td><td rowspan=1 colspan=1>47385.1</td><td rowspan=1 colspan=1>5633.9</td><td rowspan=1 colspan=1>14849.5</td><td rowspan=1 colspan=1>18827.7</td><td rowspan=1 colspan=1>18827.7</td></tr></table>

For the 2127 subjects enrolled in the study, a total of 880 subjects were adjudicated as subjects with HF and 1247 subjects were adjudicated as subjects without HF.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Subject with Heart Failure</td><td rowspan=1 colspan=1>Subject without Heart Failure</td></tr><tr><td rowspan=1 colspan=1>Age Group</td><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1>&lt; 50</td><td rowspan=1 colspan=1>34.8% (160/460)</td><td rowspan=1 colspan=1>65.2% (300/460)</td></tr><tr><td rowspan=1 colspan=1>50-75</td><td rowspan=1 colspan=1>40.9% (553/1352)</td><td rowspan=1 colspan=1>59.1% (799/1352)</td></tr><tr><td rowspan=1 colspan=1>&gt;75</td><td rowspan=1 colspan=1>53.0% (167/315)</td><td rowspan=1 colspan=1>47.0% (148/315)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sex</td><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>36.5% (376/1030)</td><td rowspan=1 colspan=1>63.5% (654/1030)</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>45.9% (504/1097)</td><td rowspan=1 colspan=1>54.1% (593/1097)</td></tr></table>

The pretest probability of adjudicated HF (prevalence of adjudicated HF in the study), posttest probabilities, and likelihood ratios of the Alere NT-proBNP for Alinity i result vs. adjudicated diagnosis (along with the $9 5 \%$ CIs) were determined based on guidance from CLSI EP12, 3rd ed., for all subjects and by sex using the age-dependent positive cutoffs (450 $\boldsymbol { \mathrm { p g / m L } }$ for subjects 18 to $< 5 0$ years of age, $9 0 0 \ : \mathrm { p g / m L }$ for subjects 50 to 75 years of age, and $1 8 0 0 ~ \mathrm { p g / m L }$ for subjects $> 7 5$ years of age) and age-independent negative cutoff (300 $\mathrm { p g / m L ) }$ ).

The results for all subjects are presented in the following tables:

Clinical Performance – All Subjects:

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n/ N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 18 - &lt;50PretestProbability ofHF (Prevalenceof HF instudy): 34.78%(160/460)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>74.5(140 / 188)(67.8, 80.2)</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>5.47(4.19, 7.13)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>35.0(7 / 20)(18.1, 56.7)</td><td rowspan=1 colspan=1>65.0(13 / 20)(43.3, 81.9)</td><td rowspan=1 colspan=1>1.01(0.41, 2.48)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>239</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>94.8(239 / 252)(91.4, 97.0)</td><td rowspan=1 colspan=1>0.10(0.06, 0.17)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>460</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 50 - 75PretestProbability of HF(Prevalence ofHF in study):40.90%(553/1352)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>437</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>585</td><td rowspan=1 colspan=1>74.7(437 / 585)(71.0, 78.1)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.27(3.67, 4.96)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>35.2(80 / 227)(29.3, 41.7)</td><td rowspan=1 colspan=1>64.8(147 / 227)(58.3, 70.7)</td><td rowspan=1 colspan=1>0.79(0.61, 1.01)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>504</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>93.3(504 / 540)(90.9, 95.1)</td><td rowspan=1 colspan=1>0.10(0.07, 0.14)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>553</td><td rowspan=1 colspan=1>799</td><td rowspan=1 colspan=1>1352</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=4 colspan=1>Age Group(years): &gt;75PretestProbability ofHF (Prevalenceof HF instudy): 53.02%(167/315)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>77.5(131 / 169)(70.6, 83.2)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3.06(2.30, 4.06)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>36.6(34 / 93)(27.5, 46.7)</td><td rowspan=1 colspan=1>63.4(59 / 93)(53.3, 72.5)</td><td rowspan=1 colspan=1>0.51(0.36, 0.73)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>96.2(51 / 53)(87.2, 99.0)</td><td rowspan=1 colspan=1>0.03(0.01, 0.14)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>167</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>315</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=4 colspan=1>All SubjectsPretestProbability ofHF (Prevalenceof HF instudy): 41.37%(880/2127)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>708</td><td rowspan=1 colspan=1>234</td><td rowspan=1 colspan=1>942</td><td rowspan=1 colspan=1>75.2(708 / 942)(72.3, 77.8)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.29(3.80, 4.83)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>340</td><td rowspan=1 colspan=1>35.6(121 / 340)(30.7, 40.8)</td><td rowspan=1 colspan=1>64.4(219 / 340)(59.2, 69.3)</td><td rowspan=1 colspan=1>0.78(0.64, 0.96)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>794</td><td rowspan=1 colspan=1>845</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>94.0(794 / 845)(92.2, 95.4)</td><td rowspan=1 colspan=1>0.09(0.07, 0.12)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>880</td><td rowspan=1 colspan=1>1247</td><td rowspan=1 colspan=1>2127</td><td></td><td></td><td></td></tr></table>

Clinical Performance – Female Subjects:

<table><tr><td colspan="1" rowspan="2">Category</td><td colspan="1" rowspan="2">NT-proBNPTest Result</td><td colspan="2" rowspan="1">AdjudicatedDiagnosis</td><td colspan="1" rowspan="2">Total</td><td colspan="1" rowspan="2">PosttestProbability ofHF % (n / N)(95% CI)</td><td colspan="1" rowspan="2">PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td colspan="1" rowspan="2">LikelihoodRatio (HF)(95% CI)</td></tr><tr><td colspan="1" rowspan="1">HF</td><td colspan="1" rowspan="1">Non-HF</td></tr><tr><td colspan="1" rowspan="4">Age Group(years): 18 - &lt;50PretestProbability ofHF (Prevalenceof HF in study):25.00% (55/220)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">69.2(45 / 65)(57.2, 79.1)</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">6.75(4.39, 10.37)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">30.0(3 / 10)(10.8, 60.3)</td><td colspan="1" rowspan="1">70.0(7 / 10)(39.7, 89.2)</td><td colspan="1" rowspan="1">1.29(0.34, 4.80)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">138</td><td colspan="1" rowspan="1">145</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">95.2(138 / 145)(90.4, 97.6)</td><td colspan="1" rowspan="1">0.15(0.08, 0.31)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">55</td><td colspan="1" rowspan="1">165</td><td colspan="1" rowspan="1">220</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="4">Age Group(years): 50 - 75PretestProbability ofHF (Prevalenceof HF in study):36.70%(236/643)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">173</td><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">229</td><td colspan="1" rowspan="1">75.5(173 / 229)(69.6, 80.7)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">5.33(4.13, 6.88)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">76</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">31.5(35 / 111)(23.6, 40.7)</td><td colspan="1" rowspan="1">68.5(76 / 111)(59.3, 76.4)</td><td colspan="1" rowspan="1">0.79(0.55, 1.15)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">275</td><td colspan="1" rowspan="1">303</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">90.8(275 / 303)(87.0, 93.5)</td><td colspan="1" rowspan="1">0.18(0.12, 0.25)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">236</td><td colspan="1" rowspan="1">407</td><td colspan="1" rowspan="1">643</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="4">Age Group(years): &gt;75PretestProbability ofHF (Prevalenceof HF in study):50.90% (85/167)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">77.1(64 / 83)(67.0, 84.8)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3.25(2.15, 4.91)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">37.0(20 / 54)(25.4, 50.4)</td><td colspan="1" rowspan="1">63.0(34 / 54)(49.6, 74.6)</td><td colspan="1" rowspan="1">0.57(0.36, 0.90)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">96.7(29 / 30)(83.3, 99.4)</td><td colspan="1" rowspan="1">0.03(0.00, 0.24)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">167</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="4">All FemaleSubjects PretestProbability ofHF (Prevalenceof HF in study):36.50%(376/1030)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">282</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">377</td><td colspan="1" rowspan="1">74.8(282 / 377)(70.2, 78.9)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">5.16(4.25, 6.27)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">175</td><td colspan="1" rowspan="1">33.1(58 / 175)(26.6, 40.4)</td><td colspan="1" rowspan="1">66.9(117 / 175)(59.6, 73.4)</td><td colspan="1" rowspan="1">0.86(0.65, 1.15)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">442</td><td colspan="1" rowspan="1">478</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">92.5(442 / 478)(89.7, 94.5)</td><td colspan="1" rowspan="1">0.14(0.10, 0.19)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">376</td><td colspan="1" rowspan="1">654</td><td colspan="1" rowspan="1">1030</td><td></td><td></td><td></td></tr><tr><td colspan="1" rowspan="2">Category</td><td colspan="1" rowspan="2">NT-proBNPTest Result</td><td colspan="2" rowspan="1">AdjudicatedDiagnosis</td><td colspan="1" rowspan="2">Total</td><td colspan="1" rowspan="2">PosttestProbability ofHF % (n/ N)(95% CI)</td><td colspan="1" rowspan="2">PosttestProbability ofNon-HF %(n / N)(95% I)</td><td colspan="1" rowspan="2">LikelihoodRatio (HF)(95% CI)</td></tr><tr><td colspan="1" rowspan="1">HF</td><td colspan="1" rowspan="1">Non-HF</td></tr><tr><td colspan="1" rowspan="4">Age Group(years): 18 - &lt;50PretestProbability ofHF (Prevalenceof HF instudy): 43.75%(105/240)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">77.2(95 / 123)(69.1, 83.8)</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">4.36(3.12, 6.10)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">40.0(4 / 10)(16.8, 68.7)</td><td colspan="1" rowspan="1">60.0(6 / 10)(31.3, 83.2)</td><td colspan="1" rowspan="1">0.86(0.25, 2.96)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">107</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">94.4(101 / 107)(88.3, 97.4)</td><td colspan="1" rowspan="1">0.08(0.03, 0.17)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">105</td><td colspan="1" rowspan="1">135</td><td colspan="1" rowspan="1">240</td><td colspan="3" rowspan="1">Y</td></tr><tr><td colspan="1" rowspan="4">Age Group(years): 50 - 75PretestProbability ofHF (Prevalenceof HF instudy): 44.71%(317/709)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">264</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">356</td><td colspan="1" rowspan="1">74.2(264 / 356)(69.4, 78.4)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3.55(2.95, 4.27)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">71</td><td colspan="1" rowspan="1">116</td><td colspan="1" rowspan="1">38.8(45 / 116)(30.4, 47.9)</td><td colspan="1" rowspan="1">61.2(71 /116)(52.1, 69.6)</td><td colspan="1" rowspan="1">0.78(0.56, 1.10)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">229</td><td colspan="1" rowspan="1">237</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">96.6(229 / 237)(93.5, 98.3)</td><td colspan="1" rowspan="1">0.04(0.02, 0.09)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">317</td><td colspan="1" rowspan="1">392</td><td colspan="1" rowspan="1">709</td><td colspan="3" rowspan="1">Y</td></tr><tr><td colspan="1" rowspan="4">Age Group(years): &gt;75PretestProbability ofHF (Prevalenceof HF instudy): 55.41%(82/148)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">67</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">77.9(67 / 86)(68.1, 85.4)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">2.84(1.92, 4.20)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">35.9(14 / 39)(22.7, 51.6)</td><td colspan="1" rowspan="1">64.1(25 / 39)(48.4, 77.3)</td><td colspan="1" rowspan="1">0.45(0.26, 0.80)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">95.7(22 / 23)(79.0, 99.2)</td><td colspan="1" rowspan="1">0.04(0.01, 0.26)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">148</td><td colspan="3" rowspan="1">Y</td></tr><tr><td colspan="1" rowspan="2">All MaleSubjects PretestProbability of HF(Prevalence of HF</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">426</td><td colspan="1" rowspan="1">139</td><td colspan="1" rowspan="1">565</td><td colspan="1" rowspan="1">75.4(426 / 565)(71.7, 78.8)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3.61(3.10, 4.19)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">165</td><td colspan="1" rowspan="1">38.2(63 / 165)(31.1, 45.8)</td><td colspan="1" rowspan="1">61.8(102 / 165)(54.2, 68.9)</td><td colspan="1" rowspan="1">0.73(0.54, 0.97)</td></tr><tr><td colspan="1" rowspan="2">in study): 45.94%(504/1097)</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">352</td><td colspan="1" rowspan="1">367</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">95.9(352 / 367)(93.4, 97.5)</td><td colspan="1" rowspan="1">0.05(0.03, 0.08)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">504</td><td colspan="1" rowspan="1">593</td><td colspan="1" rowspan="1">1097</td><td></td><td></td><td></td></tr></table>

The pretest probability of adjudicated HF (prevalence of adjudicated HF in the study), posttest probabilities, and likelihood ratios of the Alere NT-proBNP for Alinity i result vs adjudicated diagnosis (along with the $9 5 \%$ CIs) were also determined for relevant clinical subgroups using the age-dependent positive cutoffs and age-independent negative cutoff.

Clinical Performance – Subjects with History of Heart Failure:   

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 18 - &lt;50PretestProbability ofHF (Prevalenceof HF instudy): 71.70%(114/159l)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>85.8(103 / 120)(78.5, 91.0)</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>2.39(1.64, 3.50)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>62.5(5 / 8)(30.6, 86.3)</td><td rowspan=1 colspan=1>37.5(3 / 8)(13.7, 69.4)</td><td rowspan=1 colspan=1>0.66(0.16, 2.64)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>−.</td><td rowspan=1 colspan=1>80.6(25 / 31)(63.7, 90.8)</td><td rowspan=1 colspan=1>0.09(0.04, 0.22)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=3>Y</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 50 - 75PretestProbability ofHF (Prevalenceof HF instudy): 65.09%(427/656)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>344</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>426</td><td rowspan=1 colspan=1>80.8(344 / 426)(76.7, 84.2)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2.25(1.88, 2.69)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>56.3(58 / 103)(46.7, 65.5)</td><td rowspan=1 colspan=1>43.7(45 / 103)(34.5, 53.3)</td><td rowspan=1 colspan=1>0.69(0.48, 0.99)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>402</td><td rowspan=1 colspan=1>413</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>80.3(102 / 127)(72.6, 86.3)</td><td rowspan=1 colspan=1>0.13(0.09, 0.20)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>427</td><td rowspan=1 colspan=1>229</td><td rowspan=1 colspan=1>656</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=4 colspan=1>Age Group(years): &gt;75PretestProbability ofHF (Prevalenceof HF instudy): 69.31%(131/189)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>82.9(107 / 129)(75.5, 88.5)</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>2.15(1.53, 3.02)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>53.3(24 / 45)(39.1, 67.1)</td><td rowspan=1 colspan=1>46.7(21 / 45)(32.9, 60.9)</td><td rowspan=1 colspan=1>0.51(0.31, 0.83)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>100.0(15 / 15)(79.6, 100.0)</td><td rowspan=1 colspan=1>0.01(0.00, 0.24)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>189</td><td rowspan=1 colspan=3>Y</td></tr><tr><td rowspan=2 colspan=1>All Subjectswith History ofHFPretestProbability of</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>554</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>675</td><td rowspan=1 colspan=1>82.1(554 / 675)(79.0, 84.8)</td><td rowspan=1 colspan=1>−·</td><td rowspan=1 colspan=1>2.26(1.95, 2.62)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>55.8(87 / 156)(47.9, 63.3)</td><td rowspan=1 colspan=1>44.2(69 / 156)(36.7, 52.1)</td><td rowspan=1 colspan=1>0.62(0.47, 0.83)</td></tr></table>

Clinical Performance – Subjects without a History of Heart Failure:   

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=2 colspan=1>HF (Prevalenceof HF instudy): 66.93%(672/1004)</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>173</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>82.1(142 / 173)(75.8, 87.1)</td><td rowspan=1 colspan=1>0.11(0.07, 0.16)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>672</td><td rowspan=1 colspan=1>332</td><td rowspan=1 colspan=1>1004</td><td rowspan=1 colspan=3></td></tr></table>

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 18 - &lt;50PretestProbability ofHF (Prevalenceof HF in study):15.28% (46/301)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>54.4(37 / 68)(42.7, 65.7)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>6.62(4.62, 9.48)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>16.7(2 / 12)(4.7, 44.8)</td><td rowspan=1 colspan=1>83.3(10 / 12)(55.2, 95.3)</td><td rowspan=1 colspan=1>1.11(0.25, 4.90)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>214</td><td rowspan=1 colspan=1>221</td><td rowspan=1 colspan=1>−·</td><td rowspan=1 colspan=1>96.8(214 / 221)(93.6, 98.5)</td><td rowspan=1 colspan=1>0.18(0.09, 0.36)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>255</td><td rowspan=1 colspan=1>301</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=2 colspan=1>Age Group(years): 50 - 75PretestProbability ofHF (Prevalence</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=1>58.5(93 / 159)(50.7, 65.9)</td><td rowspan=1 colspan=1>−·</td><td rowspan=1 colspan=1>6.37(4.97, 8.18)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>17.7(22 / 124)(12.0, 25.4)</td><td rowspan=1 colspan=1>82.3(102 / 124)(74.6, 88.0)</td><td rowspan=1 colspan=1>0.98(0.64, 1.48)</td></tr><tr><td rowspan=2 colspan=1>of HF in study):18.10%(126/696)</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>402</td><td rowspan=1 colspan=1>413</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>97.3(402 / 413)(95.3, 98.5)</td><td rowspan=1 colspan=1>0.12(0.07, 0.22)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>570</td><td rowspan=1 colspan=1>696</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=4 colspan=1>Age Group(years): &gt;75PretestProbability ofHF (Prevalenceof HF in study):28.57% (36/126)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>60.0(24 / 40)(44.6, 73.7)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3.75(2.27, 6.19)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>20.8(10 / 48)(11.7, 34.3)</td><td rowspan=1 colspan=1>79.2(38 / 48)(65.7, 88.3)</td><td rowspan=1 colspan=1>0.66(0.37, 1.17)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>−−</td><td rowspan=1 colspan=1>94.7(36 / 38)(82.7, 98.5)</td><td rowspan=1 colspan=1>0.14(0.04, 0.55)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=3></td></tr></table>

Clinical Performance – Subjects with $\mathrm { e G F R } < 6 0 \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \mathrm { m } ^ { 2 } .$   

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=4 colspan=1>All Subjectswithout Historyof HFPretestProbability ofHF (Prevalenceof HF in study):18.52%(208/1123)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>267</td><td rowspan=1 colspan=1>57.7(154 / 267)(51.7, 63.5)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>6.00(4.96, 7.25)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>184</td><td rowspan=1 colspan=1>18.5(34 / 184)(13.5, 24.7)</td><td rowspan=1 colspan=1>81.5(150 / 184)(75.3, 86.5)</td><td rowspan=1 colspan=1>1.00(0.71, 1.40)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>652</td><td rowspan=1 colspan=1>672</td><td rowspan=1 colspan=1>−−</td><td rowspan=1 colspan=1>97.0(652 / 672)(95.4, 98.1)</td><td rowspan=1 colspan=1>0.13(0.09, 0.21)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>208</td><td rowspan=1 colspan=1>915</td><td rowspan=1 colspan=1>1123</td><td rowspan=1 colspan=3></td></tr></table>

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(5% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 18 -&lt;50PretestProbability ofHF (Prevalenceof HF in study):72.22% (39/54)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>88.1(37 / 42)(75.0, 94.8)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2.85(1.39, 5.84)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0(1 /1)(20.7, 100.0)</td><td rowspan=1 colspan=1>0.0(0 / 1)(0.0, 79.3)</td><td rowspan=1 colspan=1>1.18(0.05, 27.37)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>90.9(10 / 11)(62.3, 98.4)</td><td rowspan=1 colspan=1>0.04(0.01, 0.28)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 50 - 75PretestProbability ofHF (Prevalenceof HF in study):57.11%(237/415)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>201</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>259</td><td rowspan=1 colspan=1>77.6(201 / 259)(72.1, 82.3)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2.60(2.09, 3.24)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>35.1(27 / 77)(25.3, 46.2)</td><td rowspan=1 colspan=1>64.9(50 / 77)(53.8, 74.7)</td><td rowspan=1 colspan=1>0.41(0.26, 0.62)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>88.6(70 / 79)(79.7, 93.9)</td><td rowspan=1 colspan=1>0.10(0.05, 0.19)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>237</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>415</td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=2 colspan=1>Age Group(years): &gt;75PretestProbability of</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>78.0(78 / 100)(68.9, 85.0)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2.45(1.72, 3.49)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>42.1(16 / 38)</td><td rowspan=1 colspan=1>57.9(22 / 38)</td><td rowspan=1 colspan=1>0.50(0.29, 0.88)</td></tr></table>

Clinical Performance – Subjects with $\mathrm { e G F R } \geq 6 0 \ \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \ \mathrm { m } ^ { 2 } .$ :   

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n /N)(5% C)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=3 colspan=1>HF (Prevalenceof HF in study):59.12% (94/159)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(27.9, 57.8)</td><td rowspan=1 colspan=1>(42.2, 72.1)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>100.0(21 / 21)(84.5, 100.0)</td><td rowspan=1 colspan=1>0.02(0.00, 0.26)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=4 colspan=1>Subjects witheGFR&lt;60mL/min/1.73m2PretestProbability ofHF (Prevalenceof HF in study):58.92%(370/628)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>316</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>401</td><td rowspan=1 colspan=1>78.8(316 / 401)(74.5, 82.5)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2.59(2.17, 3.10)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>37.9(44 / 116)(29.6, 47.0)</td><td rowspan=1 colspan=1>62.1(72 / 116)(53.0, 70.4)</td><td rowspan=1 colspan=1>0.43(0.30, 0.60)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>91.0(101 / 111)(84.2, 95.0)</td><td rowspan=1 colspan=1>0.07(0.04, 0.13)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>370</td><td rowspan=1 colspan=1>258</td><td rowspan=1 colspan=1>628</td><td rowspan=1 colspan=3></td></tr></table>

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 18-&lt;50PretestProbability ofHF (Prevalenceof HF in study):30.25%(121/400)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>70.5(103 / 146)(62.7, 77.3)</td><td rowspan=1 colspan=1>−·</td><td rowspan=1 colspan=1>5.52(4.15, 7.34)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>31.6(6 / 19)(15.4, 54.0)</td><td rowspan=1 colspan=1>68.4(13 / 19)(46.0, 84.6)</td><td rowspan=1 colspan=1>1.06(0.41, 2.73)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>223</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>94.9(223 / 235)(91.3, 97.1)</td><td rowspan=1 colspan=1>0.12(0.07, 0.21)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=3 colspan=1>Age Group(years): 50 - 75PretestProbability ofHF (Prevalenceof HF in study):33.51%(312/931)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>232</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>322</td><td rowspan=1 colspan=1>72.0(232 / 322)(66.9, 76.7)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>5.11(4.18, 6.26)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>35.3(53 / 150)(28.1, 43.3)</td><td rowspan=1 colspan=1>64.7(97 / 150)(56.7, 71.9)</td><td rowspan=1 colspan=1>1.08(0.80, 1.47)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>432</td><td rowspan=1 colspan=1>459</td><td rowspan=1 colspan=1>−−</td><td rowspan=1 colspan=1>94.1(432 / 459)(91.6, 95.9)</td><td rowspan=1 colspan=1>0.12(0.09, 0.18)</td></tr></table>

Clinical Performance – Subjects with $\mathrm { B M I } \geq 3 0 \mathrm { k g } / \mathrm { m } ^ { 2 } $ :   

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>619</td><td rowspan=1 colspan=1>931</td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): &gt;75PretestProbability ofHF (Prevalenceof HF in study):46.45% (72/155)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>76.5(52 / 68)(65.1, 85.0)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3.75(2.36, 5.95)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>32.7(18 /55)(21.8, 45.9)</td><td rowspan=1 colspan=1>67.3(37 / 55)(54.1, 78.2)</td><td rowspan=1 colspan=1>0.56(0.35, 0.89)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>93.8(30 / 32)(79.9, 98.3)</td><td rowspan=1 colspan=1>0.08(0.02, 0.31)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=4 colspan=1>All Subjects witheGFR≥60mL/min/1.73m2PretestProbability ofHF (Prevalenceof HF in study):33.98%(505/1486)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>387</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>536</td><td rowspan=1 colspan=1>72.2(387 / 536)(68.3, 75.8)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>5.05(4.32, 5.89)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>224</td><td rowspan=1 colspan=1>34.4(77 / 224)(28.5, 40.8)</td><td rowspan=1 colspan=1>65.6(147 / 224)(59.2, 71.5)</td><td rowspan=1 colspan=1>1.02(0.79, 1.31)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>685</td><td rowspan=1 colspan=1>726</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>94.4(685 / 726)(92.4, 95.8)</td><td rowspan=1 colspan=1>0.12(0.09, 0.16)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>981</td><td rowspan=1 colspan=1>1486</td><td rowspan=1 colspan=3>EY</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 18 - &lt;50PretestProbability ofHF (Prevalenceof HF in study):40.75%(108/265)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>77.6(90 / 116)(69.2, 84.2)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>5.03(3.51, 7.22)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>46.7(7 / 15)(24.8, 69.9)</td><td rowspan=1 colspan=1>53.3(8 / 15)(30.1, 75.2)</td><td rowspan=1 colspan=1>1.27(0.48, 3.40)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>134</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>91.8(123 / 134)(85.9, 95.4)</td><td rowspan=1 colspan=1>0.13(0.07, 0.23)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>265</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Age Group(years): 50 - 75</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>231</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>285</td><td rowspan=1 colspan=1>81.1(231 / 285)(76.1, 85.2)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.84(3.74, 6.25)</td></tr></table>

Clinical Performance – Subjects with $\mathrm { B M I } < 3 0 \mathrm { k g / m } ^ { 2 } ;$ :   

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % (n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=3 colspan=1>PretestProbability ofHF (Prevalenceof HF in study):46.92%(328/699)</td><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>51.1(67 / 131)(42.7, 59.5)</td><td rowspan=1 colspan=1>48.9(64 / 131)(40.5, 57.3)</td><td rowspan=1 colspan=1>1.18(0.87, 1.61)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>253</td><td rowspan=1 colspan=1>283</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>89.4(253 / 283)(85.3, 92.5)</td><td rowspan=1 colspan=1>0.13(0.09, 0.19)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>328</td><td rowspan=1 colspan=1>371</td><td rowspan=1 colspan=1>699</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=4 colspan=1>Age Group(years): &gt;75PretestProbability ofHF (Prevalenceof HF in study):59.81% (64/107)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>90.6(48 / 53)(79.7, 95.9)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>6.45(2.80, 14.88)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>45.7(16 / 35)(30.5, 61.8)</td><td rowspan=1 colspan=1>54.3(19 / 35)(38.2, 69.5)</td><td rowspan=1 colspan=1>0.57(0.33, 0.97)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>100.0(19 / 19)(83.2, 100.0)</td><td rowspan=1 colspan=1>0.02(0.00, 0.28)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=2 colspan=1>All Subjects withBMI ≥ 30 kg/m2PretestProbability ofHF (Prevalence</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>369</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>454</td><td rowspan=1 colspan=1>81.3(369 / 454)(77.4, 84.6)</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>4.96(4.05, 6.07)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>181</td><td rowspan=1 colspan=1>49.7(90 / 181)(42.5, 56.9)</td><td rowspan=1 colspan=1>50.3(91 /181)(43.1, 57.5)</td><td rowspan=1 colspan=1>1.13(0.87, 1.47)</td></tr><tr><td rowspan=2 colspan=1>of HF in study):46.69%(500/1071)</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>395</td><td rowspan=1 colspan=1>436</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>90.6(395 / 436)(87.5, 93.0)</td><td rowspan=1 colspan=1>0.12(0.09, 0.16)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>571</td><td rowspan=1 colspan=1>1071</td><td rowspan=1 colspan=3></td></tr></table>

<table><tr><td colspan="1" rowspan="2">Category</td><td colspan="1" rowspan="2">NT-proBNPTest Result</td><td colspan="2" rowspan="1">AdjudicatedDiagnosis</td><td colspan="1" rowspan="2">Total</td><td colspan="1" rowspan="2">PosttestProbability ofHF % (n / N)(95% CI)</td><td colspan="1" rowspan="2">PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td colspan="1" rowspan="2">LikelihoodRatio (HF)(95% CI)</td></tr><tr><td colspan="1" rowspan="1">HF</td><td colspan="1" rowspan="1">Non-HF</td></tr><tr><td colspan="1" rowspan="3">Age Group(years): 18 - &lt;50PretestProbability ofHF (Prevalenceof HF in study):30.41% (45/148)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">73.3(44 / 60)(61.0, 82.9)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">6.29(4.00, 9.90)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0.0(0 / 4)(0.0, 49.0)</td><td colspan="1" rowspan="1">100.0(4 /4)(51.0, 100.0)</td><td colspan="1" rowspan="1">0.25(0.01, 4.60)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">98.8(83 / 84)</td><td colspan="1" rowspan="1">0.03(0.00, 0.19)</td></tr><tr><td colspan="1" rowspan="2">Category</td><td colspan="1" rowspan="2">NT-proBNPTest Result</td><td colspan="2" rowspan="1">AdjudicatedDiagnosis</td><td colspan="1" rowspan="2">Total</td><td colspan="1" rowspan="2">PosttestProbability ofHF % (n / N)(95% CI)</td><td colspan="1" rowspan="2">PosttestProbability ofNonHF %(n / N)(95% CI)</td><td colspan="1" rowspan="2">LikelihoodRatio (HF)(95% CI)</td></tr><tr><td colspan="1" rowspan="1">HF</td><td colspan="1" rowspan="1">Non-HF</td></tr><tr><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">(93.6, 99.8)</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">103</td><td colspan="1" rowspan="1">148</td><td colspan="3" rowspan="1"></td></tr><tr><td colspan="1" rowspan="4">Age Group(years): 50 - 75PretestProbability ofHF (Prevalenceof HF in study):36.46%(198/543)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">185</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">265</td><td colspan="1" rowspan="1">69.8(185 / 265)(64.0, 75.0)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">4.03(3.31, 4.90)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">69</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">11.5(9 / 78)(6.2, 20.5)</td><td colspan="1" rowspan="1">88.5(69 / 78)(79.5, 93.8)</td><td colspan="1" rowspan="1">0.23(0.12, 0.45)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">196</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">98.0(196 / 200)(95.0, 99.2)</td><td colspan="1" rowspan="1">0.04(0.01, 0.09)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">198</td><td colspan="1" rowspan="1">345</td><td colspan="1" rowspan="1">543</td><td colspan="3" rowspan="1">EY</td></tr><tr><td colspan="1" rowspan="4">Age Group(years): &gt;75PretestProbability ofHF (Prevalenceof HF in study):51.08% (95/186)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">76</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">107</td><td colspan="1" rowspan="1">71.0(76 / 107)(61.8, 78.8)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">2.35(1.73, 3.18)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">34.7(17 / 49)(22.9, 48.7)</td><td colspan="1" rowspan="1">65.3(32 / 49)(51.3, 77.1)</td><td colspan="1" rowspan="1">0.51(0.30, 0.85)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">93.3(28 / 30)(78.7, 98.2)</td><td colspan="1" rowspan="1">0.07(0.02, 0.28)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">186</td><td colspan="3" rowspan="1">EY</td></tr><tr><td colspan="1" rowspan="4">All Subjects withBMI &lt; 30 kg/m2PretestProbability ofHF (Prevalenceof HF in study):38.54%(338/877)</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">305</td><td colspan="1" rowspan="1">127</td><td colspan="1" rowspan="1">432</td><td colspan="1" rowspan="1">70.6(305 / 432)(66.1, 74.7)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3.83(3.28, 4.48)</td></tr><tr><td colspan="1" rowspan="1">Gray Zone</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">105</td><td colspan="1" rowspan="1">131</td><td colspan="1" rowspan="1">19.8(26 / 131)(13.9, 27.5)</td><td colspan="1" rowspan="1">80.2(105 / 131)(72.5, 86.1)</td><td colspan="1" rowspan="1">0.39(0.26, 0.59)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">307</td><td colspan="1" rowspan="1">314</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">97.8(307 / 314)(95.5, 98.9)</td><td colspan="1" rowspan="1">0.04(0.02, 0.08)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">338</td><td colspan="1" rowspan="1">539</td><td colspan="1" rowspan="1">877</td><td colspan="3" rowspan="1">EY</td></tr></table>

Clinical Performance – Subjects with Comorbidities:

Comorbidities include at least one of the following: diabetes, renal dysfunction (eGFR less than $6 0 ~ \mathrm { m L / m i n } / 1 . 7 3 ~ \mathrm { m } 2 )$ , hypertension, and/or chronic obstructive pulmonary disease (COPD). The sponsor described in the labeling that patients with these comorbidities had a higher rate of false positives compared to patients without these comorbidities.

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>PosttestProbability ofHF % n/N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n /N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 18 - &lt;50PretestProbability of HF(Prevalence of HFin study): 43.67%(131/300)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>77.2(115 / 149)(69.8, 83.2)</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>4.36(3.21, 5.93)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>41.2(7 / 17)(21.6, 64.0)</td><td rowspan=1 colspan=1>58.8(10 / 17)(36.0, 78.4)</td><td rowspan=1 colspan=1>0.90(0.35, 2.31)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>134</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>93.3(125 / 134)(87.7, 96.4)</td><td rowspan=1 colspan=1>0.09(0.05, 0.18)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 50 - 75PretestProbability of HF(Prevalence of HFin study): 43.23%(527/1219)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>415</td><td rowspan=1 colspan=1>136</td><td rowspan=1 colspan=1>551</td><td rowspan=1 colspan=1>75.3(415 / 551)(71.6, 78.7)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.01(3.42, 4.69)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>37.0(78 / 211)(30.7, 43.7)</td><td rowspan=1 colspan=1>63.0(133 / 211)(56.3, 69.3)</td><td rowspan=1 colspan=1>0.77(0.60, 0.99)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>423</td><td rowspan=1 colspan=1>457</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>92.6(423 / 457)(89.8, 94.6)</td><td rowspan=1 colspan=1>0.11(0.08, 0.15)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>527</td><td rowspan=1 colspan=1>692</td><td rowspan=1 colspan=1>1219</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=4 colspan=1>Age Group(years): &gt;75PretestProbability of HF(Prevalence of HFin study): 55.25%(163/295)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>78.0(128 / 164)(71.1, 83.7)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2.88(2.15, 3.85)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>40.7(33 / 81)(30.7, 51.6)</td><td rowspan=1 colspan=1>59.3(48 / 81)(48.4, 69.3)</td><td rowspan=1 colspan=1>0.56(0.38, 0.81)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>96.0(48 / 50)(86.5, 98.9)</td><td rowspan=1 colspan=1>0.03(0.01, 0.14)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>295</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=4 colspan=1>Subjects withComorbiditiesPretestProbability of HF(Prevalence of HFin study): 45.26%(821/1814)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>658</td><td rowspan=1 colspan=1>206</td><td rowspan=1 colspan=1>864</td><td rowspan=1 colspan=1>76.2(658 / 864)(73.2, 78.9)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3.86(3.41, 4.38)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>191</td><td rowspan=1 colspan=1>309</td><td rowspan=1 colspan=1>38.2(118 / 309)(32.9, 43.7)</td><td rowspan=1 colspan=1>61.8(191 / 309)(56.3, 67.1)</td><td rowspan=1 colspan=1>0.75(0.61, 0.92)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>596</td><td rowspan=1 colspan=1>641</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>93.0(596 / 641)(90.7, 94.7)</td><td rowspan=1 colspan=1>0.09(0.07, 0.12)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>821</td><td rowspan=1 colspan=1>993</td><td rowspan=1 colspan=1>1814</td><td></td><td></td><td></td></tr></table>

Clinical Performance – Subjects without Comorbidities:   

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=2 colspan=1>NT-proBNPTest Result</td><td rowspan=1 colspan=2>AdjudicatedDiagnosis</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>Posttestrobabilityof HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>PosttestProbability ofNon-HF %(n / N)(95% CI)</td><td rowspan=2 colspan=1>LikelihoodRatio (HF)(95% CI)</td></tr><tr><td rowspan=1 colspan=1>HF</td><td rowspan=1 colspan=1>Non-HF</td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 18 -&lt;-50PretestProbability ofHF (Prevalenceof HF in study):18.13% (29/160)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>64.1(25 / 39)(48.4, 77.3)</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>8.07(4.81, 13.51)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.0(0 / 3)(0.0, 56.1)</td><td rowspan=1 colspan=1>100.0(3 / 3)(43.9, 100.0)</td><td rowspan=1 colspan=1>0.64(0.03, 12.00)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>96.6(114 / 118)(91.6, 98.7)</td><td rowspan=1 colspan=1>0.16(0.06, 0.39)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=4 colspan=1>Age Group(years): 50 - 75PretestProbability ofHF (Prevalenceof HF in study):19.55% (26/133)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>64.7(22 / 34)(47.9, 78.5)</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>7.54(4.32, 13.18)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>12.5(2 / 16)(3.5, 36.0)</td><td rowspan=1 colspan=1>87.5(14 / 16)(64.0, 96.5)</td><td rowspan=1 colspan=1>0.59(0.14, 2.43)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>97.6(81 / 83)(91.6, 99.3)</td><td rowspan=1 colspan=1>0.10(0.03, 0.39)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=4 colspan=1>Age Group(years): &gt;75PretestProbability ofHF (Prevalenceof HF in study):20.00% (4/20)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>60.0(3 / 5)(23.1, 88.2)</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>6.00(1.46, 24.69)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>8.3(1 / 12)(1.5, 35.4)</td><td rowspan=1 colspan=1>91.7(11 /12)(64.6, 98.5)</td><td rowspan=1 colspan=1>0.36(0.06, 2.05)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>100.0(3 / 3)(43.9, 100.0)</td><td rowspan=1 colspan=1>0.52(0.03, 8.39)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=4 colspan=1>Subjects withoutComorbiditiesPretestProbability ofHF (Prevalenceof HF in study):18.85% (59/313)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>64.1(50 / 78)(53.0, 73.9)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>7.69(5.33, 11.08)</td></tr><tr><td rowspan=1 colspan=1>Gray Zone</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>9.7(3 / 31)(3.3, 24.9)</td><td rowspan=1 colspan=1>90.3(28 / 31)(75.1, 96.7)</td><td rowspan=1 colspan=1>0.46(0.15, 1.47)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>198</td><td rowspan=1 colspan=1>204</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>97.1(198 / 204)(93.7, 98.6)</td><td rowspan=1 colspan=1>0.13(0.06, 0.28)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>254</td><td rowspan=1 colspan=1>313</td><td></td><td></td><td></td></tr></table>

The sponsor included the following statements in their instructions for use concerning the performance of their device in ED settings in certain clinical subgroups:

Patients with a history of HF had a higher rate of false positives compared to patients without a history of HF. Of the 332 total patients with a history of HF and adjudicated as non-HF, 121 $( 3 6 . 4 \% )$ had NT-proBNP concentrations greater than or equal to agedependent cutoffs. Of the 915 total patients with no history of HF and adjudicated as non-HF, 113 $( 1 2 . 3 \% )$ had NT-proBNP concentrations greater than or equal to agedependent cutoffs. This difference is likely due to long-standing chronic elevation of NT-proBNP in patients with a previous diagnosis of HF. Results should always be assessed in conjunction with patient’s medical history, clinical examination, and other findings.

Patients with an eGFR less than $6 0 \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \mathrm { m } ^ { 2 }$ had a higher rate of false positives compared to patients with an eGFR greater than or equal to $6 0 \mathrm { m L } / \mathrm { m i n } / 1 . 7 3$ $\mathrm { { \bar { m } } } ^ { 2 }$ . Of the 258 total patients with an eGFR less than $6 0 \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \mathrm { m } ^ { 2 }$ and adjudicated as non-HF, 85 $( 3 2 . 9 \% )$ had NT-proBNP concentrations greater than or equal to age-dependent cutoffs. Of the 981 total patients with an eGFR greater than or equal to $6 0 \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \mathrm { m } ^ { 2 }$ and adjudicated as non-HF, 149 $( 1 5 . 2 \% )$ had NTproBNP concentrations greater than or equal to age-dependent cutoffs. Eight patients adjudicated as non-HF $( 0 . 6 \% )$ had an unknown eGFR. Patients with an eGFR less than $6 0 \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \mathrm { m } ^ { 2 }$ had a higher rate of false negatives $( 9 . 0 \%$ [10/111]) compared to patients with an eGFR greater than or equal to $6 0 \mathrm { m L / m i n } / 1 . 7 3 \mathrm { m } ^ { 2 } ( 5 . 6 \%$ [41/726]). All 10 of the false negatives in the eGFR less than $6 0 ~ \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 ~ \mathrm { m } ^ { 2 }$ group were from patients with a BMI greater than or equal to $3 0 \mathrm { k g } / \mathrm { m } ^ { 2 }$ . In patients with eGFR less than $6 0 ~ \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 ~ \mathrm { \bar { m } } ^ { 2 }$ , caution should be used when interpreting NT-proBNP results. Results should always be assessed in conjunction with the patient’s medical history, clinical examination, and other findings.

Patients with a BMI greater than or equal to $3 0 \mathrm { k g } / \mathrm { m } ^ { 2 }$ had a higher rate of false negatives compared to patients with a BMI less than $3 0 \mathrm { k g } / \mathrm { m } ^ { 2 }$ . Of the total observed false negatives (51/880), 41 $( 8 0 . 4 \% )$ were from patients with a BMI greater than or equal to $3 0 \mathrm { k g } / \mathrm { m } ^ { 2 }$ , 7 $( 1 3 . 7 \% )$ were from patients with a BMI less than $3 0 ~ \mathrm { k g / m } ^ { 2 }$ , and 3 $( 5 . 9 \% )$ were from patients with an unknown BMI. In patients with a BMI less than 30 $\mathrm { k g } / \mathrm { m } ^ { 2 }$ , the age greater than 75 years group had a higher rate of false negatives $( 6 . 7 \%$ [2/30]) than the other age groups. Results should always be assessed in conjunction with the patient’s medical history, clinical examination, and other findings. In patients with obesity, natriuretic peptides should be interpreted with caution.

The sponsor also included the following limitation in their labeling:

Elevated NT-proBNP concentrations may be associated with impaired renal function (estimated glomerular filtration rate $[ \mathrm { e G F R } ] < 6 0 \ \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \ \mathrm { m } 2 )$ , history of HF and other conditions such as acute coronary syndrome, atrial fibrillation, pulmonary embolism, valvular heart disease, myocarditis, pulmonary hypertension, stroke, and sepsis, which may lead to false positive results. Obesity (body mass index $[ \mathrm { B M I } ] \ge 3 0$ $\mathrm { k g } / \mathrm { m } ^ { 2 } )$ , and other conditions such as flash pulmonary edema, pericarditis, and cardiac tamponade may lower NT-proBNP concentrations, which may lead to false negative results.

# New York Heart Association (NYHA) Functional Classification

865 subjects had a NYHA functional classification. Descriptive statistics by the NYHA classification for the 865 subjects adjudicated to have HF for all subjects and for male and female subjects are presented in the table below:

<table><tr><td rowspan=2 colspan=1>Statistics</td><td rowspan=1 colspan=3>NYHA Functional Classification</td></tr><tr><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>Class III</td><td rowspan=1 colspan=1>Class IV</td></tr><tr><td rowspan=1 colspan=4>All Subjects</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>369</td><td rowspan=1 colspan=1>499</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>5535.8</td><td rowspan=1 colspan=1>5187.5</td><td rowspan=1 colspan=1>6485.6</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>6834.18</td><td rowspan=1 colspan=1>7056.92</td><td rowspan=1 colspan=1>7829.43</td></tr><tr><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>89.5</td><td rowspan=1 colspan=1>27.1</td><td rowspan=1 colspan=1>19.8</td></tr><tr><td rowspan=1 colspan=1>5th Percentile</td><td rowspan=1 colspan=1>89.5</td><td rowspan=1 colspan=1>244.0</td><td rowspan=1 colspan=1>303.0</td></tr><tr><td rowspan=1 colspan=1>25th Percentile</td><td rowspan=1 colspan=1>1319.5</td><td rowspan=1 colspan=1>989.4</td><td rowspan=1 colspan=1>1492.8</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>2846.4</td><td rowspan=1 colspan=1>2817.5</td><td rowspan=1 colspan=1>3928.2</td></tr><tr><td rowspan=1 colspan=1>75th Percentile</td><td rowspan=1 colspan=1>7399.7</td><td rowspan=1 colspan=1>6230.9</td><td rowspan=1 colspan=1>8349.3</td></tr><tr><td rowspan=1 colspan=1>95th Percentile</td><td rowspan=1 colspan=1>23734.0</td><td rowspan=1 colspan=1>20653.1</td><td rowspan=1 colspan=1>22086.6</td></tr><tr><td rowspan=1 colspan=1>Max</td><td rowspan=1 colspan=1>23734.0</td><td rowspan=1 colspan=1>60716.9</td><td rowspan=1 colspan=1>59178.1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Male Subjects</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>206</td><td rowspan=1 colspan=1>290</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>5469.9</td><td rowspan=1 colspan=1>5955.9</td><td rowspan=1 colspan=1>6475.2</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>7566.03</td><td rowspan=1 colspan=1>7674.86</td><td rowspan=1 colspan=1>7547.84</td></tr><tr><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>89.5</td><td rowspan=1 colspan=1>166.7</td><td rowspan=1 colspan=1>19.8</td></tr><tr><td rowspan=1 colspan=1>5th Percentile</td><td rowspan=1 colspan=1>89.5</td><td rowspan=1 colspan=1>365.8</td><td rowspan=1 colspan=1>375.5</td></tr><tr><td rowspan=1 colspan=1>25th Percentile</td><td rowspan=1 colspan=1>1954.8</td><td rowspan=1 colspan=1>1221.8</td><td rowspan=1 colspan=1>1599.4</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>2846.4</td><td rowspan=1 colspan=1>3702.6</td><td rowspan=1 colspan=1>4094.2</td></tr><tr><td rowspan=1 colspan=1>75th Percentile</td><td rowspan=1 colspan=1>5415.8</td><td rowspan=1 colspan=1>7202.5</td><td rowspan=1 colspan=1>8515.5</td></tr><tr><td rowspan=1 colspan=1>95th Percentile</td><td rowspan=1 colspan=1>23734.0</td><td rowspan=1 colspan=1>21410.7</td><td rowspan=1 colspan=1>21598.1</td></tr><tr><td rowspan=1 colspan=1>Max</td><td rowspan=1 colspan=1>23734.0</td><td rowspan=1 colspan=1>60716.9</td><td rowspan=1 colspan=1>59178.1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Female Subjects</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>209</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>5667.6</td><td rowspan=1 colspan=1>4216.4</td><td rowspan=1 colspan=1>6500.1</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>6135.91</td><td rowspan=1 colspan=1>6073.57</td><td rowspan=1 colspan=1>8222.56</td></tr><tr><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>264.5</td><td rowspan=1 colspan=1>27.1</td><td rowspan=1 colspan=1>22.8</td></tr><tr><td rowspan=1 colspan=1>5th Percentile</td><td rowspan=1 colspan=1>264.5</td><td rowspan=1 colspan=1>149.2</td><td rowspan=1 colspan=1>159.4</td></tr><tr><td rowspan=1 colspan=1>25th Percentile</td><td rowspan=1 colspan=1>492.6</td><td rowspan=1 colspan=1>749.2</td><td rowspan=1 colspan=1>1266.5</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>4542.9</td><td rowspan=1 colspan=1>2172.1</td><td rowspan=1 colspan=1>3713.5</td></tr><tr><td rowspan=1 colspan=1>75th Percentile</td><td rowspan=1 colspan=1>11967.5</td><td rowspan=1 colspan=1>5022.1</td><td rowspan=1 colspan=1>8159.8</td></tr><tr><td rowspan=1 colspan=1>95th Percentile</td><td rowspan=1 colspan=1>13320.3</td><td rowspan=1 colspan=1>19295.7</td><td rowspan=1 colspan=1>24566.4</td></tr><tr><td rowspan=1 colspan=1>Max</td><td rowspan=1 colspan=1>13320.3</td><td rowspan=1 colspan=1>38880.9</td><td rowspan=1 colspan=1>47385.1</td></tr></table>

# D Clinical Cut-Off:

The sponsor describes the following cut-offs for patients presenting to ED settings where new onset or exacerbation of HF is suspected:

<table><tr><td rowspan=1 colspan=1>Age Group(Years)</td><td rowspan=1 colspan=1>NT-proBNP(pg/mL)</td><td rowspan=1 colspan=1>Interpretation</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>&lt; 300.0</td><td rowspan=1 colspan=1>Negative: HF unlikely</td></tr><tr><td rowspan=1 colspan=1>18 to &lt; 50</td><td rowspan=1 colspan=1>≥ 300.0 to &lt; 450.0</td><td rowspan=3 colspan=1>Grayzone: IndeterminateConsider other causes ofNT-proBNP elevation.</td></tr><tr><td rowspan=1 colspan=1>50 to 75</td><td rowspan=1 colspan=1>≥ 300.0 to &lt; 900.0</td></tr><tr><td rowspan=1 colspan=1>&gt;75</td><td rowspan=1 colspan=1>≥ 300.0 to &lt; 1800.0</td></tr><tr><td rowspan=1 colspan=1>18 to &lt; 50</td><td rowspan=1 colspan=1>≥ 450.0</td><td rowspan=1 colspan=1>Positive: HF likely</td></tr><tr><td rowspan=1 colspan=1>50 to 75</td><td rowspan=1 colspan=1>≥ 900.0</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=1>&gt;75</td><td rowspan=1 colspan=1>≥ 1800.0</td></tr></table>

# E Expected Values/Reference Range:

A reference interval study was performed based on guidance from CLSI EP28-A3c.

K2EDTA plasma specimens were obtained from a total of 861 apparently healthy individuals (≥ 18 years old, 442 females and 419 males) from 3 external clinical sites located in the US. The age-range distribution and sex of the individuals are described in the table below:

The exclusion criteria used to exclude subjects were:

current smoker   
known cardiac condition and/or cardiac disease   
high blood pressure (hypertension)   
kidney disease $( \mathrm { e G F R } < 6 0 \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \mathrm { m } ^ { 2 } )$   
diabetes $\left( \mathrm { H b } \mathrm { A l c } \geq 6 . 5 \% \right)$   
active cancer or diagnosis of cancer within the last five years   
previous stroke   
lung disease within the last five years   
thyroid disease   
recently reported high cholesterol or triglycerides   
reported abnormal troponin $( > 9 9$ th percentile or cutoff for normal)   
female known to be pregnant   
previous enrollment in this study

The specimens were tested with the Alere NT-proBNP for Alinity i assay on the Alinity i system. Based on the results, the $9 5 \%$ reference interval of an apparently healthy population for each sex and age range was determined to be as follows:

<table><tr><td colspan="1" rowspan="1">Age Range</td><td colspan="1" rowspan="1">Sex</td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">Median(pg/mL)</td><td colspan="1" rowspan="1">Reference Interval(2.5th to 97.5th Percentile)(pg/mL)</td></tr><tr><td colspan="1" rowspan="2">18 to &lt; 50 years old</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">181</td><td colspan="1" rowspan="1">30.7</td><td colspan="1" rowspan="1">&lt; 15.8 to 104.8</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">137</td><td colspan="1" rowspan="1">&lt;15.8</td><td colspan="1" rowspan="1">&lt; 15.8 to 180.3</td></tr><tr><td colspan="1" rowspan="2">50 to 75 years old</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">134</td><td colspan="1" rowspan="1">51.7</td><td colspan="1" rowspan="1">&lt; 15.8 to 334.1</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">146</td><td colspan="1" rowspan="1">39.9</td><td colspan="1" rowspan="1">&lt; 15.8 to 451.6</td></tr><tr><td colspan="1" rowspan="2">&gt; 75 years old</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">127</td><td colspan="1" rowspan="1">81.4</td><td colspan="1" rowspan="1">&lt; 15.8 to 956.1</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">136</td><td colspan="1" rowspan="1">65.1</td><td colspan="1" rowspan="1">&lt; 15.8 to 683.0</td></tr></table>

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.